Keros Therapeutics, Inc. (KROS) — 10-Q Filings
All 10-Q filings from Keros Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Keros Swings to Profit on Soaring License Revenue, Plans $375M Capital Return
— Nov 5, 2025 Risk: medium
Keros Therapeutics, Inc. reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $110.475 million, a -
Keros Therapeutics' Q2 Net Loss Widens to $45.2M Amid R&D Push
— Aug 6, 2025 Risk: high
Keros Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss fo -
Keros Therapeutics Files Q3 2024 10-Q
— Nov 6, 2024 Risk: medium
Keros Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results for the third quarter and the first -
Keros Therapeutics Files Q2 2024 10-Q
— Aug 7, 2024 Risk: medium
Keros Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and the first six -
Keros Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: low
Keros Therapeutics, Inc. (KROS) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Keros Therapeutics, Inc. filed a 10-Q report for the period ending
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX